Poxel Announces Completion of Patient Enrollment for TIMES 1 Trial in the Phase 3 Registration Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan Jul 3, 2018
New Imeglimin Data Demonstrating Pancreatic Beta-Cell Protection Presented at the American Diabetes Association 78th Scientific Sessions Jun 25, 2018
Poxel Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference Apr 4, 2018
Poxel to Report Full Year 2017 Results on March 22, 2018 After Market Close and Host Conference Call at 7:00 PM CET (Paris time) / 2:00 PM EDT (New York time) Mar 15, 2018
Poxel Announces Initiation of TIMES 2 and TIMES 3 Trials for the Phase 3 Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan Mar 13, 2018
Poxel Announces Participation at the Cowen 38th Annual Healthcare Conference and Oppenheimer 28th Annual Healthcare Conference Mar 7, 2018
Poxel Presents Preclinical Proof-of-Concept Data for PXL770 in Non-Alcoholic Steatohepatitis (NASH) at Global NASH Congress 2018 Feb 27, 2018
Roivant and Poxel Announce Strategic Agreement for Development and Commercialization of Imeglimin in the U.S., Europe, and Additional Countries Worldwide Feb 12, 2018
